{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T08:39:50Z","timestamp":1778747990335,"version":"3.51.4"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[1983,1,1]],"date-time":"1983-01-01T00:00:00Z","timestamp":410227200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[1983]]},"DOI":"10.1007\/bf01037939","type":"journal-article","created":{"date-parts":[[2005,1,18]],"date-time":"2005-01-18T13:43:32Z","timestamp":1106055812000},"page":"307-312","source":"Crossref","is-referenced-by-count":30,"title":["Ketanserin in essential hypertension: Effects during rest and exercise"],"prefix":"10.1007","volume":"25","author":[{"given":"B.","family":"Persson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Hedner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Berglund","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"issue":"Suppl 1","key":"CR1","first-page":"875","volume":"13","author":"E Agabiti-Rosei","year":"1982","unstructured":"Agabiti-Rosei E, Alicandri CI, Beschi M, Castellano M, Furiello R, Montini E, Muisan ML, Romanelli G, Muisan G (1982) The acute and chronic hypotensive effect of labetalol and the relationship with pretreatment plasma noradrenaline levels. Br J Clin Pharmacol 13 [Suppl 1]: 875?925","journal-title":"Br J Clin Pharmacol"},{"key":"CR2","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1161\/01.RES.38.2.109","volume":"38","author":"J Champlain De","year":"1976","unstructured":"De Champlain J, Farley L, Consineau D, van Ameringen MR (1976) Circulatory catecholamine levels in human and experimental hypertension. Circ Res 38: 109?114","journal-title":"Circ Res"},{"key":"CR3","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/S0140-6736(81)92331-X","volume":"1","author":"J Cree De","year":"1981","unstructured":"De Cree J, Verhagen H, Symoens J (1981) Acute blood-pressure-lowering effect of ketanserin. Lancet 1: 1161?1162","journal-title":"Lancet"},{"key":"CR4","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1016\/S0140-6736(81)92352-7","volume":"1","author":"J-C Demoulin","year":"1981","unstructured":"Demoulin J-C, Bertholet M, Soumagne D, David J-L, Kulbertus HE (1981) 5-HT receptor blockade in the treatment of heart failure. Lancet 1: 1186?1188","journal-title":"Lancet"},{"key":"CR5","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1097\/00005344-198209000-00020","volume":"4","author":"JR Fozard","year":"1982","unstructured":"Fozard JR (1982) Mechanism of the hypotensive effect of ketanserin. J Cardiovasc Pharmacol 4: 829?838","journal-title":"J Cardiovasc Pharmacol"},{"key":"CR6","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1152\/physrev.1960.40.1.27","volume":"40","author":"ED Fries","year":"1960","unstructured":"Fries ED (1960) Hemodynamics of hypertension. Physiol Rev 40: 27?54","journal-title":"Physiol Rev"},{"key":"CR7","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/j.1365-2125.1983.tb04974.x","volume":"16","author":"T Hedner","year":"1983","unstructured":"Hedner T, Persson B, Berglund G (1983) Ketanserin, a novel 5-hydroxy-tryptamine antagonist: monotherapy in essential hypertension. Br J Clin Pharmacol 16: 121?125","journal-title":"Br J Clin Pharmacol"},{"key":"CR8","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/0024-3205(79)90384-9","volume":"25","author":"P Hjemdahl","year":"1979","unstructured":"Hjemdahl P, Daleskog M, Kahan T (1979) Determination of plasma catecholamines by high performance liquid chromatography with electrochemical determination. Life Sci 25: 131?138","journal-title":"Life Sci"},{"issue":"Suppl 4","key":"CR9","first-page":"735","volume":"55","author":"DH Jones","year":"1978","unstructured":"Jones DH, Hamilton CA, Reid JL (1978) Plasma noradrenaline, age and blood pressure, a population study. Clin Sci Molec Med 55 [Suppl 4]: 735?755","journal-title":"Clin Sci Molec Med"},{"key":"CR10","first-page":"227","volume":"222","author":"HO Kalkman","year":"1982","unstructured":"Kalkman HO, Timmermans PBMWM, Van Zwieten PA (1982) Characterization of the antihypertensive properties of ketanserin (R 41468) in rats. J Pharmacol Exp Ther 222: 227?231","journal-title":"J Pharmacol Exp Ther"},{"key":"CR11","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1042\/cs057177s","volume":"57","author":"W Kiowski","year":"1979","unstructured":"Kiowski W, van Brummelen P, Buhler FR (1979) Plasma noradrenaline correlates with ?-adrenoceptor mediated vasoconstriction and blood pressure in patients with essential hypertension. Clin Sci 57: 1775?1805","journal-title":"Clin Sci"},{"key":"CR12","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/0014-2999(82)90599-4","volume":"81","author":"PM Lauderon","year":"1982","unstructured":"Lauderon PM, Janssen PAJ, Leysen J (1982) In vivo binding of3H ketanserin on serotonin S2-receptors in rat brain. Eur J Pharmacol 81: 43?48","journal-title":"Eur J Pharmacol"},{"key":"CR13","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/0024-3205(81)90747-5","volume":"28","author":"JE Leysen","year":"1981","unstructured":"Leysen JE, Awouters F, Kennis L, Lauderon PM, Vandenberk J, Janssen PAJ (1981) Receptor binding profile of R 41468, a novel antagonist at 5-HT2 receptors. Life Sci 28: 1015?1022.","journal-title":"Life Sci"},{"key":"CR14","doi-asserted-by":"crossref","first-page":"343s","DOI":"10.1042\/cs059343s","volume":"59","author":"P Lund-Johansen","year":"1980","unstructured":"Lund-Johansen P (1980) State of the art review: Hemodynamics in essential hypertension. Clin Sci 59: 343s-354s","journal-title":"Clin Sci"},{"key":"CR15","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1365-2125.1977.tb00712.x","volume":"4","author":"G Nyberg","year":"1977","unstructured":"Nyberg G (1977) Indirect blood pressure and heart rate measured quickly without observer bias using a semiautomatic machine (Auto-Manometer) ? response to isometric exercise in normally healthy males and its modification by?-adrenoceptor blockade. Br J Clin Pharmacol 4: 275?281","journal-title":"Br J Clin Pharmacol"},{"key":"CR16","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/S0378-4347(00)86149-6","volume":"272","author":"PO Okonkwo","year":"1983","unstructured":"Okonkwo PO, Reimann IW, Woestenborghs R, Klotz U (1983) High performance liquid chromatographic assay, with fluorometric detection of ketanserin, a new antihypertensive agent and serotonin S2 antagonist in human plasma, blood and urine. J Chromatogr 272: 411?416","journal-title":"J Chromatogr"},{"key":"CR17","unstructured":"Persson B, Hedner T, Berglund G (1983) Treatment of hypertension with ketanserin, a serotonin (S2) antagonist. Abstract. II World Conference on Clinical Pharmacology and Therapeutics, p 36"},{"key":"CR18","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/j.2042-7158.1982.tb04753.x","volume":"34","author":"B Persson","year":"1982","unstructured":"Persson B, Hedner T, Henning M (1982) Cardiovascular effects in the rat of ketanserin, a novel 5-hydroxytryptamine receptor blocking agent. J Pharm Pharmacol 34: 442?445","journal-title":"J Pharm Pharmacol"},{"key":"CR19","first-page":"217","volume":"218","author":"JM Nueten Van","year":"1981","unstructured":"Van Nueten JM, Janssen PAJ, van Beck J. Xhonneux R, Verbeuren TJ, Vanhoutte PM (1981) Vascular effects of ketanserin (R 41468), a novel antagonist at 5-HT2 serotonergic receptors. J Pharmacol Exp Ther 218: 217?230","journal-title":"J Pharmacol Exp Ther"},{"key":"CR20","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1136\/bmj.284.6315.537","volume":"284","author":"GJ Wenting","year":"1982","unstructured":"Wenting GJ, Man in't Veld AJ, Woittiez AJ, Boomsma F, Schalekamp MADH (1982) Treatment of hypertension with ketanserin, a new selective 5-HT2 receptor antagonist. Br Med J 284: 537?539","journal-title":"Br Med J"},{"key":"CR21","doi-asserted-by":"crossref","unstructured":"Wenting GJ, Man in't Veld AJ. Woittiez AJ, Boomsma F, Schalekamp MADH (1983) Hemodynamic effects of ketanserin, a new selective 5-hydroxy-tryptamine (serotonin) receptor antagonist, in essential hypertension. Clin Sci (in press)","DOI":"10.1042\/cs063435s"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF01037939.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF01037939\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF01037939","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,5]],"date-time":"2020-04-05T10:27:28Z","timestamp":1586082448000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF01037939"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1983]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[1983]]}},"alternative-id":["BF01037939"],"URL":"https:\/\/doi.org\/10.1007\/bf01037939","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[1983]]}}}